Researchers recommend dolutegravir (DTG)‐based antiretrovirals should become the first option for HIV treatment in India, following a study into DTG’s cost-effectiveness.
Research reveals that most gay and bisexual men who stop taking pre-exposure prophylaxis (PrEP) in the USA do so because it is too expensive or they see themselves as no longer having a need for it.
In the run up to World Tuberculosis (TB) Day (March 24), the European Centre for Disease Prevention and Control (ECDC) and the World Health Organization reveal the region is off- target to end TB by 2030.
First off, it’s not all about condoms... Believe it or not, condoms aren’t the only way to prevent HIV anymore.
PrEP, undetectable, on treatment … what does it all mean? Here we give you a quick run through in our jargon-busting blog.
HIV stigma is the greatest barrier to fighting the global HIV epidemic. On world Zero Discrimination Day, we challenge everyday stigma by sharing experiences from around the world.
New study reveals the extent of the relationship between gay-related stigma and HIV among men who have sex with men in Nigeria.
New research marks welcome step to make trans women in sub-Saharan Africa visible in HIV data.
There is no cure or vaccine for HIV – we debunk myths and rumours which suggest there are.
Get a reality check on some of the most bizarre rumours about how HIV is transmitted.
Let's clear up the confusion around testing — because there’s no good reason to put off getting an HIV test
New study shows people living with HIV still expect far less from their lives compared to those who are HIV-negative, despite near-normal life expectancy.
On World Development Information Day, we look at an innovative HIV self-testing app being introduced to all UNAIDS Fast-Track Cities which aims to bridge the divide between testing, treatment and care.
Mandatory HIV testing is a ‘knee-jerk and untenable reaction’, and it ultimately does not get more people testing for HIV.
A study of gay men in Malawi reveals very low levels of HIV testing and treatment access nationwide – with distinct geographic disparities in HIV prevalence that need to be taken into consideration and addressed.
Key HIV drugs added to the list of medicines critical to public health, including tenofovir for HIV prevention, and dolutegravir.
